Copp

Copp or Copps may refer to:

Coppé

Coppé (pronounced Co-pa'y, often also typed Coppe') is a Japanese electronic music singer-songwriter and music producer. She has released fifteen solo albums on her self-owned Mango + Sweetrice label.

Early life

Coppé was born and raised in Tokyo. Her real name is Yoshimi, which means pure, good and beautiful in Japanese. She was given the nickname Coppé by her mother because on her birth day she resembled a loaf of bread of the same name.

As a child, Coppé travelled frequently between Japan and Hawaii, and also lived for a while in Arizona. She studied classical piano and ballet from the age of three. As a child she won a　"Best Song for Children" of Nihon Record Taisho award (sometimes called "Japanese Grammy") for her song "Peke No Uta", which was released via King Records. She also won a Chibikko Nodojiman award while still in elementary school singing her original song "Red Red Balloon". Also while still a child she began to appear regularly on a weekly NHK TV show "Uta Wa Tomodachi". This led to her getting involved with radio, her first regular show being "All Night Nippon". She later also had shows on FM Tokyo and FM Yokohama. Her English language skills led to her being on NHK show based on learning English. Other TV shows in which she made regular appearances were TBS's "Jikan Desuyo" and "Ginza Now", NTV's "Shower Gang" and the music program "Poppers MTV" where she interviewed many foreign artists including Ray Charles, Bob Marley, James Brown, Madonna, the Police, Cyndi Lauper and Michael Jackson. After her father's death, she relocated to Honolulu in order to be closer to her mother. In Hawaii she also had a radio program on KIKI AM 83.

COPP (chemotherapy)

COPP is a chemotherapy regimen for treatment of Hodgkin disease, consisting of concurrent treatment with (C)yclophosphamide, (O)ncovin, (P)rocarbazine and (P)rednisone.

It contains less procarbazine than MOPP (procarbazine is given only for 10 days in cycle instead of 14), and the very toxic mechlorethamine, which is prone to give severe neutropenia and to severely heighten the risk of secondary malignancies, is changed to less toxic cyclophosphamide, which is more safe to the progenitor stem cells (thus, less neutropenia) and less prone to give late secondary malignancies.

Thus, the COPP regimen is considered more safe and less toxic than MOPP. But it offsets with somewhat less efficacy, especially in advanced-stage Hodgkin disease.

Nevertheless, both the COPP and the MOPP are now supplanted by ABVD, which is less toxic and more effective than either COPP or MOPP.

Dosage